← All trials
NCT05664750
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- May 28, 2023
- Completion date
- Aug 15, 2023
- First posted
- Dec 26, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 675
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Trinomab Biotech Co., Ltd.Lead sponsor
- Peking UniversityOverall official - principal investigator
- Guangzhou Trinomab Biotech Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.